Efficacy and Safety of RC28-E Versus Aflibercept

NCT05727397 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

432

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG: RC28-E
DRUG: Aflibercept

Sponsor

RemeGen Co., Ltd.